Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clonogenic assay for urologic malignancies.

T Hashimura, N Tanigawa, K Okada

    Gan
    |August 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Esophago-bronchial fistula caused by chemotherapy with bronchial artery infusion for pulmonary metastases from urinary tract cancer].

    Hinyokika kiyo. Acta urologica Japonica·1992
    Same author

    Clinical features of patients suffering from Streptococcus milleri infections--a retrospective analysis.

    Fukuoka igaku zasshi = Hukuoka acta medica·1992
    Same author

    Tumor-associated M(r) 34,000 and M(r) 32,000 membrane glycoproteins that are serine phosphorylated specifically in bovine leukemia virus-induced lymphosarcoma cells.

    Cancer research·1992
    Same author

    Modulation by intracellular calcium pool of arginine vasopressin-induced cellular cyclic AMP production in rat renal papillary collecting tubule cells in culture.

    The Journal of pharmacology and experimental therapeutics·1992
    Same author

    Sex determination by discriminant function analysis of lateral cranial form.

    Forensic science international·1992
    Same author

    [Serial MRI findings in neuro-Behçet disease].

    No shinkei geka. Neurological surgery·1992

    In vitro chemosensitivity testing using soft agar assays shows promise for guiding urologic cancer treatment. While uroepithelial cancer sensitivity matched clinical results, renal cell cancers demonstrated higher in vitro drug sensitivity.

    Area of Science:

    • Oncology
    • Pharmacology
    • Cancer Biology

    Background:

    • Urologic cancers, including renal cell, uroepithelial, prostatic, and testicular types, present diverse treatment challenges.
    • Predicting patient response to chemotherapy remains a critical unmet need in managing these malignancies.

    Purpose of the Study:

    • To evaluate the efficacy of an in vitro soft agar clonogenic assay for assessing chemosensitivity in human urologic tumors.
    • To compare in vitro drug sensitivity results with established clinical outcomes for different urologic cancer subtypes.

    Main Methods:

    • Culturing 91 human urologic tumor specimens (37 renal cell, 40 uroepithelial, 7 prostatic, 7 testicular) using a double soft agar technique.
    • Performing chemosensitivity testing on specimens that achieved sufficient growth (≥30 colonies/plate).

    Related Experiment Videos

  • Analyzing response rates to various chemotherapeutic agents including mitomycin C, 5-fluorouracil, cisplatin, bleomycin, and vincristine.

    • Main Results:

    • A high overall tumor growth rate (77%) was achieved in the soft agar assay.
    • Significant in vitro sensitivity (≥10% response) was observed for renal cell cancers with multiple agents and for uroepithelial cancers with vincristine and cisplatin.
    • In vitro sensitivity rates for uroepithelial cancers closely mirrored clinical findings, whereas renal cell cancers showed considerably higher in vitro sensitivity than clinically observed.

    Conclusions:

    • In vitro chemosensitivity testing via clonogenic assay appears to be a valuable tool for urologic cancer treatment selection.
    • A universal definition of drug sensitivity is not applicable across all urologic tumor types, necessitating tailored assay interpretation.
    • Further research and validation are warranted to optimize the clinical application of in vitro chemosensitivity assays for personalized urologic oncology.